Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)

Deerfield, Ill., January 25, 2013, and Osaka, Japan, January 26, 2013 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

“Takeda is pleased with the FDA approval of NESINA, OSENI and KAZANO for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience,” said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. “Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population.”

to continue, click here
http://www.takeda.com/news/2013/20130126_5626.html

Tags: Takeda, Type2, algogliptin

Views: 256

Reply to This

Replies to This Discussion

Nesina (alogliptin) is a drug of the class DPP-4. Others include Januvia (sitagliptin), Onglyza (saxagliptin) and Gavus (vildagliptin)(approved in the EU, but not the US). These drugs inhibit the GLP-1 and GIP pathways and have been found to drop your A1c by about 0.5%. There are some who believe that the GLP-1 class of drugs are inherently more effective.

It is nice to see "competition." But this is a me too type of thing, we already have two expensive options, this is yet a third which is not any more effective than options already on the market. In fact, a real criticism is metformin monotherapy is more effective than DPP-4 monotherapy, but still I regularly hear of fellow patients put on these expensive medications as a first medication.

So, I greet this anouncement with a hearty "Whoop de doo."

RSS

Advertisement



REsources

From the Diabetes Hands Foundation blog...

FDA Docket Extended! We Need You.

If you are new to diabetes advocacy in the traditional sense of the word, you may be thinking, “What the heck is a docket!?” I certainly was the first twenty times I heard it (yes it took that long). For Read on! →

An Open Letter from @AskManny, @DiabetesHF to @NYTRosenthal, @NYTimes

Dear Ms. Rosenthal: I am a person living with type 1 diabetes since the age of 30. I am also the President and co-Founder of the Diabetes Hands Foundation, a nonprofit aimed at connecting and mobilizing the diabetes community. Seeing Read on! →

Diabetes Hands Foundation Team

DHF TEAM

Manny Hernandez
(Co-Founder, Editor, has LADA)

Emily Coles
(Head of Communities, has type 1)

Mila Ferrer
(EsTuDiabetes Community Manager, mother of a child with type 1)

Mike Lawson
(Head of Experience, has type 1)

Corinna Cornejo
(Development Manager, has type 2)

Heather Gabel
(Administrative and Programs Assistant, has type 1)

DHF VOLUNTEERS


Lead Administrator
Bradford (has type 1)

Administrators
Lorraine (mother of type 1)
Marie B (has type 1)

Brian (bsc) (has type 2)

Gary (has type 2)

David (dns) (type 2)

 

LIKE us on Facebook

Spread the word

Loading…

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.

© 2014   A community of people touched by diabetes, run by the Diabetes Hands Foundation.

Badges  |  Contact Us  |  Terms of Service